Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3456

World Non Small-Cell Lung Cancer Market - Opportunities and Forecasts, 2017-2023

LI_18666
Pages: NA
Jul 2018 | 925 Views
face gplus_n
Author's : NA
Tables: NA
Charts: NA
twit_n pr_n

Non-small cell Lung cancer is the malignant tissue formation in the lung, usually in the cell lining air passage, which is characterized by abnormal cell growth in lung tissue. Globally, lung cancer is one of the leading causes of death since the past several decades. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012. Furthermore, it is estimated that ~158,040 Americans are would die due to lung cancer by 2015. According to the American Society of cancer, non small-cell lung cancer accounts for ~85% to 90% of overall lung cancer cases and the trend is expected to grow with the same momentum. Thus, a large patient base of non small-cell lung cancer depicts the unmet need for diagnosis and treatment. It has been observed that non small-cell lung cancer is the most prevalent type of lung cancer commonly caused due to active and passive smoking. 

Conventionally, the treatment pattern for non-small cell lung cancer is focussed around chemotherapy. Surgery is not suitable for most of the people diagnosed with lung cancer, thus, chemotherapy remains the cornerstone for non-small cell lung cancer treatment. However, emergence of targeted therapies for patients has widened the scope of NSCLC treatment by providing lesser side effects and effective treatments as compared to chemotherapy. The launch of new drugs in several new drugs classes would address the potential unmet need among NSCLC patients over the forecast period. The potential drivers for lung cancer therapeutic market include active & passive tobacco smoking, geriatric population and improper lifestyle. However, the availability of generic drugs, limited treatment options and unmet need of diagnosis might hamper the market. Chemotherapy and radiation therapy poses a bigger challenge in terms of adverse effects arising from treatment. Thus, key players have shifted their focus towards innovative therapies and safer therapeutics. For example, on April 20, 2015, global strategic partner Pfizer and Merck initiated the phase III study for Avelumb, to assess its safety and efficacy as compared to docetaxel in the patients with non-small cell lung cancer. 

Global non small-cell lung cancer market is segmented into types, therapeutics and geography. Based on the types, global non small-cell lung cancer market is further segmented into squamous cell carcinoma, adenocarcinoma, large cell carcinoma and others. The market is segmented on the basis of therapeutics into chemotherapy, targeted therapy, surgery, radiotherapy and pipeline drugs. Furthermore, the market is segmented, on the basis of geography, across North America, Europe, Asia-Pacific and LAMEA. Key players profiled in the market are Pfizer, Roche, AstraZeneca, Eli Lily, GlaxoSmithKline, Novartis AG, Merck & Co., and Agennix AG. Collaboration, product launch and acquisition are some of the strategies adopted by key players in the non-small cell lung cancer market. For example, on April 21, 2015, Pfizer received the USFDA approval for potential treatment of patients with ROS1-positive non-small cell lung cancer. On November 21, 2014, GSK collaborated with Clovis oncology to design clinical trials for the evaluation of new combination therapy used in NSCLC treatments. 

KEY MARKET BENEFITS

  • The report provides a quantitative analysis of the current market and estimations through 2014‐2020 that help identify the prevailing market opportunities 

  • Non small cell lung cancer market conditions are comprehensively analyzed based on region 

  • Key market players within the non small cell lung cancer market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding the competitive outlook of the market 

  • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework

  • Comprehensive analysis of factors that drive and restrict the growth of the global non-small cell lung cancer market, is provided in the report

  • Exhaustive analysis of the global non-small cell lung cancer devices market by therapeutics type helps in understanding the types of therapeutics that are currently being used along with the variants that would gain prominence in future

KEY MARKET SEGMENTS

Global non small-cell lung cancer market is segmented as below:

  • Global non small-cell lung cancer market- by Type

    • Squamous cell (epidermoid) carcinoma

    • Adenocarcinoma

    • Large cell (undifferentiated) carcinoma

    • Other

  • Global non small-cell lung cancer market- by Therapy

    • Chemotherapy

    • Targeted therapy

    • Surgery

    • Radiotherapy

    • Laser therapy 

    • Photodynamic therapy (PDT)

    • Others

  • Global non small-cell lung cancer market- by Geography

    • North America

    • Europe

    • Asia-Pacific

    • LAMEA

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
World Non Small-Cell Lung Cancer Market- Opportunities and Forecasts, 2014 - 2022

  • Online Only
  • $3456
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo